Cencora, Inc. $COR Stock Holdings Increased by Swmg LLC

Swmg LLC raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 34.5% in the third quarter, HoldingsChannel reports. The institutional investor owned 5,937 shares of the company’s stock after purchasing an additional 1,523 shares during the quarter. Cencora accounts for about 0.6% of Swmg LLC’s portfolio, making the stock its 25th largest holding. Swmg LLC’s holdings in Cencora were worth $1,951,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Baader Bank Aktiengesellschaft lifted its stake in Cencora by 318.5% during the second quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after buying an additional 3,300 shares in the last quarter. Focus Partners Wealth increased its position in shares of Cencora by 25.8% in the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after acquiring an additional 1,171 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Cencora by 947.5% during the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after acquiring an additional 232,539 shares during the period. Fiduciary Alliance LLC purchased a new stake in shares of Cencora in the 2nd quarter valued at approximately $262,000. Finally, Martin Capital Partners LLC boosted its stake in Cencora by 205.2% in the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after purchasing an additional 2,544 shares during the period. Institutional investors own 97.52% of the company’s stock.

Insider Activity

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 20,317 shares of company stock worth $7,009,260. 10.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. TD Cowen upped their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Mizuho raised their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, Wells Fargo & Company raised their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus target price of $379.50.

Cencora Stock Performance

Shares of COR stock opened at $335.73 on Friday. Cencora, Inc. has a fifty-two week low of $233.61 and a fifty-two week high of $377.54. The stock’s 50-day moving average is $349.89 and its two-hundred day moving average is $318.27. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm has a market cap of $65.13 billion, a P/E ratio of 42.23, a PEG ratio of 1.60 and a beta of 0.66.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the company earned $3.34 EPS. The firm’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.